Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program: Blood Cancer Journal

A. Rambaldi, A. Iurlo, A.M. Vannucchi, B. Martino, A. Guarini, M. Ruggeri, N. von Bubnoff, M. De Muro, M.F. McMullin, S. Luciani, V. Martinelli, A. Nogai, V. Rosti, A. Ricco, P. Bettica, S. Manzoni, S. Di Tollo

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article number53
JournalBlood Cancer J.
Volume11
Issue number3
DOIs
Publication statusPublished - 2021

Keywords

  • acetylsalicylic acid
  • busulfan
  • clopidogrel
  • givinostat
  • hydroxyurea
  • interferon
  • ticlopidine
  • adult
  • aged
  • Article
  • asthenia
  • cancer diagnosis
  • combination drug therapy
  • compassionate use
  • computer assisted tomography
  • controlled study
  • diarrhea
  • drug efficacy
  • drug safety
  • drug tolerability
  • eye disease
  • female
  • follow up
  • gastrointestinal disease
  • human
  • hypertension
  • long term care
  • major clinical study
  • male
  • mental disease
  • myeloproliferative neoplasm
  • neurologic disease
  • nuclear magnetic resonance imaging
  • nutritional disorder
  • overall response rate
  • phase 1 clinical trial
  • phase 2 clinical trial
  • phlebotomy
  • polycythemia vera
  • single blind procedure
  • thrombocythemia
  • thrombocytopenia
  • thromboembolism
  • treatment duration
  • treatment response
  • vascular disease

Cite this